Sanofi registers Phase 3 extension study for lunsekimig in COPD, named COLOSSUS

This week's update centers on a single new Sanofi registry entry for its COPD program.

• Sanofi is recruiting for a Phase 3 open-label extension study, "COLOSSUS" (NCT07793409), evaluating lunsekimig in adults with inadequately controlled chronic obstructive pulmonary disease characterized by an eosinophilic phenotype who completed prior studies EFC18243 or EFC18244¹. The trial enrolls an estimated 1508 participants and involves subcutaneous administration of lunsekimig for up to 96 weeks¹, with a primary endpoint tracking exposure-adjusted incidence rate of treatment-emergent adverse events, including adverse events of special interest and serious adverse events, from baseline to Week 100¹. The study began recruiting on 2026-09-16 and has an estimated primary completion date of 2031-07-23.